Faster Forward with Accelerated First in Human to Proof Of Concept Early Phase Vaccine Trials

Faster Forward with Accelerated First in Human to Proof Of Concept Early Phase Vaccine Trials

Contract Research

Information

This presentation from Dr. Zori Cheshmedzhieva, Vice-President, Global Clinical Development, Celerion covers: - The Sky is NOT Falling: Executing a Vaccine Study during the Pandemic - How Hybrid Study Design Approaches Decrease Proof of Concept Timelines -Adaptive Design Execution Experts: Rapid Start-up, Fast Track to Patients and Real-time Bioanalysis Data Feedback
CelerionCelerion, a leader in early clinical research services and clinical bioanalysis, is a global company with over 50 years of experience. Our unique combination of medical expertise, clinical operations experience and scientific excellence provides our customers with the guidance to make fast, accurate decisions about their drug development. Celerion has proven experience across a variety of vaccines, including different routes of administration, and patient populations. Our track record spans both preventive and therapeutic vaccines, subunit, and conjugates across all phases I-IV in more than 20 countries, 300 study centers and 4500 subjects.

Log in